2011 ASCO Annual Meeting Press Program Announced

For Immediate Release
April 28, 2011

Susie Tappouni

-May 18 Presscast-
-June 3-6: Onsite Press Conferences in Chicago-

ALEXANDRIA, Va. – The American Society of Clinical Oncology (ASCO) today announced the studies to be featured in the 2011 ASCO Annual Meeting press program. The press program will include important new research on therapies for melanoma, ovarian cancer and pediatric cancers, cancer prevention and screening advances, and novel targeted agents.

The ASCO Annual Meeting will take place in Chicago, Friday, June 3 – Tuesday, June 7 and attract more than 30,000 oncology professionals from around the globe. This year, which marks the 40th anniversary of the signing of the National Cancer Act, more than 4,000 abstracts will be presented or published at the Meeting, covering the latest advances in clinical cancer research and reinforcing the theme of this year’s meeting, “Patients. Pathways. Progress.”

The majority of Annual Meeting abstracts will be publicly posted on Wednesday, May 18 at 6:00 PM (EDT). ASCO will host an embargoed presscast for media at 12:00 noon (EDT) that day to highlight seven noteworthy studies. Plenary, Late-breaking and Clinical Review abstracts will be released on site at the meeting. The full media and embargo policies and the press program schedule-at-a-glance are available.

Wednesday, May 18 – Embargoed Presscast (12:00 noon EDT):

  • Findings from a large, long-term study – the Prostate, Lung, Colorectal and Ovarian (PLCO) Screening Trial – evaluating the value of CA-125 and transvaginal ultrasound for early detection of ovarian cancer in a general population of healthy women.
  • Results from a large, population-based study of Swedish men assessing whether prostate-specific antigen (PSA) levels between the ages of 44 and 50 predict long-term risk of prostate cancer metastasis or death up to 30 years later.
  • A randomized, Phase II trial evaluating the effectiveness of a novel targeted agent called cabozantinib in patients with various types of advanced solid tumors.
  • Results of a randomized, double-blind, placebo-controlled Phase II trial of maintenance therapy with the PARP inhibitor olaparib in patients with relapsed ovarian cancer.
  • Findings from a large study on the effectiveness of human papillomavirus (HPV) testing alone or in combination with cervical cytology (Pap smear) for identifying women at high risk for developing cervical cancer.
  • A genome-wide association study (GWAS) to determine biomarkers that predict which patients are at the greatest risk for developing taxane-induced neuropathy.
  • A double-blind, prospective study on the effect of cigarette smoking, fitness, and alcohol use on cancer outcomes among women at high risk of breast cancer in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (BCPT).

Friday, June 3, 1:00 PM (CDT) – Opening Press Conference – Marking 40 Years of Progress Against Cancer: The opening press briefing will focus on progress made in the treatment, prevention, and diagnosis of cancer in the 40 years since the passage of the National Cancer Act. ASCO’s president, George W. Sledge, MD, will compare cancer care in 1971 with today and discuss how care may evolve in the future. In addition, the briefing will highlight progress made in recent years and that continues to be made, including the presentation of results of two important clinical trials:

  • Findings from a Children’s Oncology Group study to be featured in ASCO’s Plenary session comparing a high-dose methotrexate regimen with a long-time standard treatment regimen for children and young adults with high-risk acute lymphoblastic leukemia.
  • Results of a novel phase I clinical trials program exploring a new strategy for testing and matching targeted therapies to the molecular tumor profiles of patients with advanced cancer.

Saturday, June 4, 10:30 AM (CDT) – Women’s Cancers Press Briefing:

  • Findings from the first large randomized Phase III trial to assess the use of an aromatase inhibitor for preventing breast cancer in postmenopausal women at increased risk for the disease.
  • A large, randomized trial looking at the benefits of adding regional nodal irradiation to women with high-risk, node-negative or node-positive breast cancer.
  • Results from a randomized, double-blinded, Phase III trial of chemotherapy with or without bevacizumab (Avastin) in women with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
  • Findings from a study investigating safety and efficacy of adding bevacizumab to standard chemotherapy in women with newly diagnosed ovarian cancer.

Saturday, June 4, 1:30 PM (CDT) – Developmental Therapeutics Press Briefing:

  • A Phase I/II study to assess the safety, pharmacokinetics, and efficacy of a combination of oral MEK and BRAF inhibitors in patients with BRAF V600-positive solid tumors.
  • Results of the National Cancer Institute’s Lung Cancer Mutation Consortium (LCMC) study to identify driver mutations in tumors from patients with advanced lung cancer.
  • Randomized, Phase III study assessing circulating tumor cells as a potential biomarker for treatment effectiveness and overall survival in patients with metastatic castration-resistant prostate cancer.
  • A randomized Phase III, study comparing the efficacy and safety of ruxolitinib versus best available therapy in patients with primary myelofibrosis, post-polycythemia vera-myelofibrosis or post-essential thrombocythemia-myelofibrosis.

Sunday, June 5, 8:00 AM (CDT) – Cancer as a Chronic Disease Press Briefing:

  • Findings from a Phase III randomized trial evaluating the use of flaxseed to reduce hot flashes in postmenopausal women. Hot flashes are a common side effect among women undergoing long-term hormonal breast cancer treatment.
  • Final results of a multicenter, randomized Phase III study, to be highlighted in ASCO’s Plenary session, comparing adjuvant imatinib (Gleevac) for 12 months versus 36 months for the treatment of patients with GIST at high risk of recurrence.
  • A Phase III trial investigating the effectiveness of maintenance therapy with pemetrexed (Alimta) immediately following treatment with pemetrexed and cisplatin (Platinol, Platinol-AQ) to induce remission in patients with advanced non-small cell lung cancer.
  • Results from the first national survey of U.S. primary care physicians and medical oncologists about their perceptions of existing barriers in providing long-term breast and colorectal cancer survivorship care.

Sunday, June 5, 10:00 AM (CDT) – Trials That Set New Standards of Care Press Briefing:
Note: All trials featured in this press briefing will be presented in ASCO’s Plenary session.

  • Results from a head-to-head study of the impact on survival of two chemotherapy regimens in high-risk neuroblastoma, one of the most common types of pediatric cancer.
  • A Phase III trial comparing treatment with a BRAF inhibitor (vemurafenib) or with dacarbazine in melanoma patients with V600E BRAF mutations.
  • Findings from a Phase III study of ipilimumab (Yervoy), a targeted monoclonal antibody, plus dacarbazine versus dacarbazine alone as first-line treatment for stage III or IV melanoma patients.

Monday, June 6, 10:00 AM (CDT) – Responding to the Global Cancer Crisis Press Briefing: Leaders from ASCO, the Union for International Cancer Control, and the American Cancer Society will provide first-hand perspective on the global state of cancer care, with a focus on the growing cancer burden in low- and middle-income countries. The groups will discuss their call to action for U.S. and international policymakers leading up to the United Nations’ first General Assembly Summit on Non-communicable Diseases in September in New York. The leaders will also announce new efforts to improve cancer care in developing countries, which have severe shortages of oncologists and very limited access to state-of-the-art cancer treatments, screening services and palliative care.

Media Resources and Facilities

  • Media Registration: To register for the embargoed May 18 Presscast or to attend the ASCO Annual Meeting, please visit ASCO’s Media Headquarters at www.asco.org/mediahq. Registration must be completed no later than May 17 to participate in the embargoed May 18 Presscast. Annual Meeting pre-registration for U.S. and international journalists is required and must be completed by Friday, May 20, 2011.
  • On-site Resources: A full-service Press Room will provide wireless Internet, telephones, fax, scanner, printers, and limited computer workstations with Internet access. A limited number of private interview rooms will also be available. Leading cancer experts will be available to speak with members of the press upon request.
  • Photos from the ASCO Annual Meeting and press briefings will be available through ASCO’s online Press Center each day of the Meeting. Media requests for specific photos are welcome and accommodated to the greatest degree possible.
  • Shuttle service between Annual Meeting hotels and the convention center will be available.
  • ASCO’s Virtual Meeting will provide online access to all major sessions following the meeting.
  • Access to the Virtual Press Room – an online repository of corporate and institutional press materials created by third-party organizations.


About ASCO
The American Society of Clinical Oncology (ASCO) is the world's leading professional organization representing physicians who care for people with cancer. With nearly 30,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs, and peer-reviewed journals. Patient-oriented cancer information is available at www.cancer.net.